blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3389695

EP3389695 - INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  27.01.2023
Database last updated on 22.05.2024
FormerExamination is in progress
Status updated on  18.03.2022
FormerRequest for examination was made
Status updated on  21.09.2018
FormerThe international publication has been made
Status updated on  23.06.2017
Most recent event   Tooltip27.01.2023Application deemed to be withdrawnpublished on 01.03.2023  [2023/09]
Applicant(s)For all designated states
The Walter and Eliza Hall Institute of Medical Research
1G Royal Parade
Parkville, VIC 3052 / AU
[2018/43]
Inventor(s)01 / HUNTINGTON, Nicholas D.
C/- The Walter and Eliza Hall Institute of Medical
Research
1G Royal Parade
Parkville Victoria 3052 / AU
02 / NICHOLSON, Sandra E.
C/- The Walter and Eliza Hall Institute of Medical
Research
1G Royal Parade
Parkville Victoria 3052 / AU
03 / BABON, Jeff
C/- The Walter and Eliza Hall Institute of Medical
Research
1G Royal Parade
Parkville Victoria 3052 / AU
04 / KOLESNIK, Tatiana
C/- The Walter and Eliza Hall Institute of Medical
Research
1G Royal Parade
Parkville Victoria 3052 / AU
 [2018/43]
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[N/P]
Former [2018/43]Chapman, Paul Gilmour
Marks & Clerk LLP
40 Torphichen Street
Edinburgh EH3 8JB / GB
Application number, filing date16874152.816.12.2016
[2018/43]
WO2016AU51252
Priority number, dateAU2015090522016.12.2015         Original published format: AU 2015905220
[2018/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017100861
Date:22.06.2017
Language:EN
[2017/25]
Type: A1 Application with search report 
No.:EP3389695
Date:24.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 22.06.2017 takes the place of the publication of the European patent application.
[2018/43]
Search report(s)International search report - published on:AU22.06.2017
(Supplementary) European search report - dispatched on:EP10.09.2019
ClassificationIPC:A61K38/17, A61K35/17, A61K31/7088, A61K39/395, A61P35/00, A61P31/12, A61P37/04, G01N33/566, A61K31/506, A61K31/713, C07K16/18, A61K39/00, A61P35/02, C07K16/28, G01N33/68, C07K16/22
[2019/41]
CPC:
C07K16/2818 (EP,AU,CN,US); A61K31/506 (EP,AU,CN,US); A61K31/713 (EP,AU,CN,US);
A61K35/17 (US); A61K38/04 (AU,US); A61K38/1709 (EP,AU,CN,US);
A61K39/395 (EP,AU,CN,US); A61K39/4613 (EP,AU,CN); A61K39/4644 (EP,AU,CN);
A61P31/00 (CN); A61P31/12 (CN); A61P31/14 (CN);
A61P31/16 (CN); A61P31/20 (CN); A61P31/22 (CN);
A61P35/00 (EP,AU,CN,US); A61P35/02 (EP,AU,CN,US); A61P35/04 (CN);
C07K16/18 (EP,AU,CN,US); C07K16/22 (EP,AU,CN,US); C07K16/2803 (EP,AU,CN,US);
C12N5/0646 (EP,AU,CN,US); G01N33/15 (CN); G01N33/566 (EP,AU,CN,US);
G01N33/6863 (EP,AU,CN,US); A61K2039/505 (EP,AU,CN,US); A61K2039/507 (EP,AU,CN,US);
A61K2239/31 (EP,AU,CN); A61K2239/38 (EP,AU,CN); A61K2239/46 (EP,AU,CN);
A61K2239/48 (EP,AU,CN); A61K2239/49 (EP,AU,CN); A61K2239/55 (EP,AU,CN);
A61K2239/57 (EP,AU,CN); Y02A50/30 (EP) (-)
Former IPC [2018/43]A61K38/17, A61K35/17, A61K31/7088, A61K39/395, A61P35/00, A61P31/12, A61P37/04, G01N33/566
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/43]
TitleGerman:HEMMUNG VON CYTOKININDUZIERTEM SH2-PROTEIN IN NK-ZELLEN[2018/43]
English:INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS[2018/43]
French:INHIBITION DE PROTÉINES SH2 INDUITES PAR DES CYTOKINES DANS DES CELLULES NK[2018/43]
Entry into regional phase15.06.2018National basic fee paid 
15.06.2018Search fee paid 
15.06.2018Designation fee(s) paid 
15.06.2018Examination fee paid 
Examination procedure15.06.2018Examination requested  [2018/43]
15.06.2018Date on which the examining division has become responsible
06.04.2020Amendment by applicant (claims and/or description)
17.03.2022Despatch of a communication from the examining division (Time limit: M06)
28.09.2022Application deemed to be withdrawn, date of legal effect  [2023/09]
19.10.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2023/09]
Divisional application(s)EP20213615.6  / EP3827838
EP23173594.5
Fees paidRenewal fee
15.06.2018Renewal fee patent year 03
22.10.2019Renewal fee patent year 04
20.10.2020Renewal fee patent year 05
19.10.2021Renewal fee patent year 06
31.10.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2012078540  (US HEALTH [US], et al) [I] 1-15* See claims *;
 [I]  - DOUGLAS C. PALMER ET AL, "Cish actively silences TCR signaling in CD8 + T cells to maintain tumor tolerance", THE JOURNAL OF EXPERIMENTAL MEDICINE, US, (20151102), vol. 212, no. 12, doi:10.1084/jem.20150304, ISSN 0022-1007, pages 2095 - 2113, XP055391183 [I] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1084/jem.20150304
International search[X]WO0020624  (SAHLTECH AB [SE], et al) [X] 34, 36, 46, 50, 52 and 57 * see Claims *;
 [X]WO0037636  (INST MEDICAL W & E HALL [AU], et al) [X] 34-36 and 57 * see pp. 10-15 and Claims *;
 [X]WO0132912  (SAHLTECH AB [SE], et al) [X] 46, 51, 52 and 57 * see Claims and Examples *;
 [X]US2002147307  (HILTON DOUGLAS J [AU], et al) [X] 57 * see Example 40 *;
 [X]US2003022311  (DUNNINGTON DAMIEN D [US], et al) [X] 34, 36, 50, 52 and 57 * see Claims and [0073-0087] *;
 [XY]WO2006112869  (BAYLOR COLLEGE MEDICINE [US], et al) [X] 1, 8, 10-16, 23-33, 53, 55 and 57 * see Claims see Claims * [Y] 9, 17, 21-22;
 [X]US2007179089  (NORTON RAYMOND S [AU], et al) [X] 36-38, 44 and 57 * see Figure 5, [0121], Example 7, and Claims *;
 [XY]WO2012078540  (US HEALTH [US], et al) [X] 1, 8, 11-15, 24-33, 53, 55 and 57 * see Claims and Examples see Claims and Examples * [Y] 9, 16, 17, 21-22;
 [A]US2012282646  (CHOI INPYO [KR], et al) [A] 1-64* see Examples and Claims *;
 [XY]  - AMAN, M. et al., "CIS Associates with the Interleukin-2 Receptor b Chain and Inhibits Interleukin-2-dependent Signaling", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (19990000), vol. 274, no. 42, pages 30266 - 30272, XP055391180 [X] 57 * see pp. 30268 see Figure 3, 7 and 8 * [Y] 9, 16, 17, 21

DOI:   http://dx.doi.org/10.1074/jbc.274.42.30266
 [X]  - GE, D. et al., "LNCaP Prostate Cancer Cells with Autocrine Interleukin-6 Expression Are Resistant to IL -6-induced Neuroendocrine Differentiation due to Increased Expression of Suppressors of Cytokine Signaling", PROSTATE., (20120000), vol. 72, no. 12, pages 1306 - 1316, XP055391181 [X] 57 * see pp. 4 *

DOI:   http://dx.doi.org/10.1002/pros.22479
 [X]  - HASHIMOTO, K. et al., "RSV replication is attenuated by counteracting expression of the suppressor of cytokine signaling (SOCS) molecules", VIROLOGY, vol. 391, no. 2, pages 162 - 170, XP026458372 [X] 57 * see Table 1 *
 [X]  - PALMER, D. et al., "Cish actively silences TCR signaling in CD 8+ T cells to maintain tumor tolerance", JOURNAL OF EXPERIMENTAL MEDICINE, (20150000), vol. 212, no. 12, pages 2095 - 2113, XP055391183 [X] 57 * see pp. 2100-01 and Figure 5 *

DOI:   http://dx.doi.org/10.1084/jem.20150304
 [X]  - HU, G. et al., "MicroRNA-98 and let-7 Confer Cholangiocyte Expression of Cytokine-Inducible Src Homology 2-Containing Protein in Response to Microbial Challenge", THE JOURNAL OF IMMUNOLOGY, (20090000), vol. 183, pages 1617 - 1624, XP055391187 [X] 57 * see pp. 1619 *

DOI:   http://dx.doi.org/10.4049/jimmunol.0804362
 [Y]  - PIESSEVAUX, J. et al., "Elongin B/C Recruitment Regulates Substrate Binding by CIS", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20080000), vol. 283, no. 31, pages 21334 - 21346, XP055391189 [Y] 22 * see Introduction *

DOI:   http://dx.doi.org/10.1074/jbc.M803742200
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.